196 related articles for article (PubMed ID: 29496349)
1. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.
Osowicki J; Vekemans J; Kaslow DC; Friede MH; Kim JH; Steer AC
Vaccine; 2018 Jun; 36(24):3397-3405. PubMed ID: 29496349
[TBL] [Abstract][Full Text] [Related]
2. The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics.
Vekemans J; Gouvea-Reis F; Kim JH; Excler JL; Smeesters PR; O'Brien KL; Van Beneden CA; Steer AC; Carapetis JR; Kaslow DC
Clin Infect Dis; 2019 Aug; 69(5):877-883. PubMed ID: 30624673
[TBL] [Abstract][Full Text] [Related]
3. Clinical development strategy for a candidate group A streptococcal vaccine.
Schödel F; Moreland NJ; Wittes JT; Mulholland K; Frazer I; Steer AC; Fraser JD; Carapetis J
Vaccine; 2017 Apr; 35(16):2007-2014. PubMed ID: 28318768
[TBL] [Abstract][Full Text] [Related]
4. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.
Kobayashi M; Schrag SJ; Alderson MR; Madhi SA; Baker CJ; Sobanjo-Ter Meulen A; Kaslow DC; Smith PG; Moorthy VS; Vekemans J
Vaccine; 2019 Nov; 37(50):7307-7314. PubMed ID: 28017431
[TBL] [Abstract][Full Text] [Related]
5. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics.
Vekemans J; Moorthy V; Friede M; Alderson MR; Sobanjo-Ter Meulen A; Baker CJ; Heath PT; Madhi SA; Mehring-Le Doare K; Saha SK; Schrag S; Kaslow DC
Vaccine; 2019 Nov; 37(50):7391-7393. PubMed ID: 29398277
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes.
Burlet E; HogenEsch H; Dunham A; Morefield G
AAPS J; 2017 May; 19(3):875-881. PubMed ID: 28283948
[TBL] [Abstract][Full Text] [Related]
7. An Experimental Group A
Rivera-Hernandez T; Carnathan DG; Jones S; Cork AJ; Davies MR; Moyle PM; Toth I; Batzloff MR; McCarthy J; Nizet V; Goldblatt D; Silvestri G; Walker MJ
mBio; 2019 Apr; 10(2):. PubMed ID: 31040243
[TBL] [Abstract][Full Text] [Related]
8. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.
Kuo CF; Tsao N; Hsieh IC; Lin YS; Wu JJ; Hung YT
PLoS One; 2017; 12(3):e0174464. PubMed ID: 28355251
[TBL] [Abstract][Full Text] [Related]
10. Group A streptococcal vaccines: paving a path for accelerated development.
Dale JB; Fischetti VA; Carapetis JR; Steer AC; Sow S; Kumar R; Mayosi BM; Rubin FA; Mulholland K; Hombach JM; Schödel F; Henao-Restrepo AM
Vaccine; 2013 Apr; 31 Suppl 2():B216-22. PubMed ID: 23598485
[TBL] [Abstract][Full Text] [Related]
11. Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease-streptococcal vaccine development: a national heart, lung and blood institute workshop report.
Fulurija A; Cunningham MW; Korotkova N; Masterson MY; Bansal GP; Baker MG; Cannon JW; Carapetis JR; Steer AC
BMJ Glob Health; 2023 Dec; 8(Suppl 9):. PubMed ID: 38164699
[No Abstract] [Full Text] [Related]
12. Vaccine development for group A streptococcus infections and associated disease.
Batzloff MR; Sriprakash KS; Good MF
Curr Drug Targets; 2004 Jan; 5(1):57-69. PubMed ID: 14738218
[TBL] [Abstract][Full Text] [Related]
13. Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.
Lee GM; Salomon JA; Gay C; Hammitt JK
Health Qual Life Outcomes; 2010 Mar; 8():28. PubMed ID: 20226042
[TBL] [Abstract][Full Text] [Related]
14. Development of Group A streptococcal vaccines: an unmet global health need.
Sheel M; Moreland NJ; Fraser JD; Carapetis J
Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880
[TBL] [Abstract][Full Text] [Related]
15. Knowing is half the battle: targeting virulence factors of group A Streptococcus for vaccine and therapeutics.
Thomas CL; Lee SW
Curr Drug Targets; 2012 Mar; 13(3):308-22. PubMed ID: 22206254
[TBL] [Abstract][Full Text] [Related]
16. A Controlled Human Infection Model of Group A
Osowicki J; Azzopardi KI; McIntyre L; Rivera-Hernandez T; Ong CY; Baker C; Gillen CM; Walker MJ; Smeesters PR; Davies MR; Steer AC
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760615
[TBL] [Abstract][Full Text] [Related]
17. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
18. Working towards a group A streptococcal vaccine: report of a collaborative Trans-Tasman workshop.
Moreland NJ; Waddington CS; Williamson DA; Sriskandan S; Smeesters PR; Proft T; Steer AC; Walker MJ; Baker EN; Baker MG; Lennon D; Dunbar R; Carapetis J; Fraser JD
Vaccine; 2014 Jun; 32(30):3713-20. PubMed ID: 24837510
[TBL] [Abstract][Full Text] [Related]
19. Current status of group A streptococcal vaccine development.
Dale JB
Adv Exp Med Biol; 2008; 609():53-63. PubMed ID: 18193657
[TBL] [Abstract][Full Text] [Related]
20. Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.
Nakakana U; Serry-Bangura A; Edem BE; Tessitore P; Di Cesare L; Moriel DG; Podda A; De Ryck IS; Arora AK
Drugs R D; 2024 Mar; 24(1):1-12. PubMed ID: 38494581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
